Oxurion Publishes 2021 Annual Report
25 Mars 2022 - 10:11PM
Leuven, BELGIUM, Boston, MA, US - March
25, 2022 – 09.00 PM CET
– Oxurion NV (Euronext Brussels:
OXUR) (the “Company” or “Oxurion”), a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, with clinical stage assets in vascular
retinal disorders, published its annual report for the financial
year 2021.
The annual report for the year ended 2021 is
available in the “Investors” section of the Company’s website and
can also be downloaded as a PDF.
About Oxurion Oxurion (Euronext
Brussels: OXUR) is a biopharmaceutical company developing next
generation standard of care ophthalmic therapies, which are
designed to better preserve vision in patients with retinal
vascular disorders including diabetic macular edema (DME), the
leading cause of vision loss in diabetic patients worldwide as well
as other conditions, including wet age-related macular degeneration
(wet AMD) and macular edema following retinal vein occlusion
(ME-RVO). Oxurion is aiming to build a leading global franchise in
the treatment of retinal vascular disorders based on the successful
development of its two novel therapeutics. THR-149 is a potent
plasma kallikrein inhibitor being developed as a potential new
standard of care for the up to 50% of DME patients showing
suboptimal response to anti-VEGF therapy. THR-687 is a highly
selective pan-RGD integrin antagonist that is being developed as a
potential first line therapy for DME patients as well as wet AMD
and potentially ME-RVO. Oxurion is headquartered in Leuven,
Belgium, with corporate operations in Boston, MA. More information
is available at www.oxurion.com.
For more information, please contact:
Oxurion NVTom GraneyChief Executive OfficerTel:
+32 16 75 13 10tom.graney@oxurion.com Michaël
DillenChief Business OfficerTel: +32 479 783
583michael.dillen@oxurion.com |
EUMEDiSTRAVA ConsultingDavid
Dible/ Sylvie Berrebi/Frazer HallTel: +44 203 928
6900oxurion@medistrava.com
USWestwicke, an ICR
CompanyChristopher BrinzeyTel: +1 617 835
9304chris.brinzey@westwicke.com |
Oxurion NV (EU:OXUR)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Oxurion NV (EU:OXUR)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024